Cardiovascular risk assessment in the metabolic syndrome, screening for subclinical disease, and implications for treatment

British Journal of Diabetes and Vascular Disease

Volumn 5, Issue 6, 2005, Pages 305-314

  Wong, Nathan D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coronary heart disease; Epidemiology; Metabolic syndrome; Prevention; Subclinical atherosclerosis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; C REACTIVE PROTEIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; METFORMIN; NICOTINIC ACID; ROSUVASTATIN; TRIACYLGLYCEROL;

ALGORITHM; ANKLE BRACHIAL INDEX; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIET RESTRICTION; DIET THERAPY; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; ECHOGRAPHY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; METABOLIC SYNDROME X; MORTALITY; OBESITY; PATHOGENESIS; PHYSICAL ACTIVITY; PREDICTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SECONDARY PREVENTION; WEIGHT REDUCTION;

EID: 30544438373     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514050050060201     Document Type: Review

References (39)

1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
2. Third report of the National Cholesterol Education Program (NCEP) expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel 111): final report. Circulation 2002;106:3143-421.
3. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care 2005;28:2745-9.
4. Ko GT, Cockram CS, Chow CC et al. High prevalence of metabolic syndrome in Hong Kong Chinese-comparison of three diagnostic criteria. Diab Res Clin Pract 2005;69:160-8.
5. Tillin T, Forhouhi N, Johnston DG et al. Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: a UK population-based cross-sectional study. Dibetologia, 2005;48:649-56.
6. Hu G, Qiao Q, Tuomilehto J et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004;164:1066-76.
7. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart Lung and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
8. Malik S, Wong ND, Franklin SS et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States Adults. Circulation 2004:110:1239-44.
9. Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study Circulation 2003;108:414-19.
10. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
11. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005;28:1769-78.
12. Wong ND, Pio JR, Franklin SS et al. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003;91:1421-6.
13. Hunt KJ Resendez RG, Williams K, Haffner SM, Stern MP; San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110:1251-7.
14. International Diabetes Federation. Worldwide definition of the metabolic syndrome. Available at: http://www.idf.org/webdata/docs/IDF-Metasyndrome-definition.pdf. Accessed August 24, 2005.
15. Rutter MK, Meigs JB, Sullivan LM et al. C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in the Framingham Offspring Study Circulation 2004;110:380-5.
16. Malik S, Wong ND, Frankin SS, Pio J, Fairchild C, Chen R. Cardiovascular Disease in US Persons with Metabolic Syndrome, Diabetes, and Elevated C-Reactive Protein. Diabetes Care 2005;28:690-3.
17. Vu JD, Vu JB, Pio JR et al. Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, diabetes mellitus and pre-existing cardiovascular disease. Am J Cardiol 2005;96:655-8.
18. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
19. O'Leary DH, Polak JF, Kronmal RA et al. for the Cardiovascular Health Study Collaborative Research Group: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14-22.
20. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6.
21. Criqui MH, Langer RD, Fronek A, Feigelson HS. Coronary disease and stroke in patients with large vessel peripheral arterial disease. Drugs 1991;42(suppl 5):16-21.
22. Wong ND, Hsu JC, Detrano RC, Diamond G, Eisenberg H, Gardin JM. Coronary artery calcium evaluation by electron beam computed tomography: relation to new cardiovascular events. Am J Cardiol 2000;86:495-8.
23. Arad Y, Spadaro LA, Goodman K, Newstein D, Guerci AD. Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol 2000;36:1253-60.
24. Kondos GT, Hoff JA, Sevrukov A et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5,635 initially asymptomatic low to intermediate-risk adults. Circulation 2003; 107:2571-6.
25. Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium for all-cause mortality. Radiology 2003;228:826-33.
26. O'Malley PG, Taylor AJ, Jackson JL, Doherty TM, Detrano RC. Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asyptomatic populations. Am J Cardiol 2000;85:945-8.
27. Wilson PWF, Smith SC, Blumenthal RS, Burke GL, Wong ND. Task Force #4 - How do we select patients for atherosclerosis imaging? In: 34th Bethesda Conference: can atherosclerosis imaging techniques improve the detection of patients at risk for ischemic heart disease. J Am Coll Cardiol 2003;41:1898-906.
28. Wong ND, Sciammarella MG, Polk D et al. The metabolic syndrome, diabetes, and subclinical atherosclerosis assessed by coronary calcium. J Am Coll Cardiol 2003;41:1547-53.
29. Ellison RC, Zhang Y, Wagenknect LE et al. Relation of the metabolic syndrome to calcified atherosclerotic plaque in the coronary arteries and aorta. Am J Cardiol 2005;95:1180-6.
30. Kullo RJ, Cassidy AE, Peyser PA et al. Association between metabolic syndrome and subclinical coronary atherosclerosis in asymptomatic adults. Am J Cardiol 2004;94:1554-8.
31. Wong ND, Rozanski AR, Gransar H et al. Metabolic syndrome increases the likelihood of inducible myocardial ischemia among patients with subclinical atherosclerosis. Diabetes Care 2005;28:1445-50.
32. Ahluwalia N, Drouet L, Ruidavets JB et al. Metabolic syndrome is associated with markers of subclinical atherosclerosis in a French population-based sample. Atherosclerosis 2005;26(epub)(in press).
33. Burchfiel CM, Skelton TN, Andrew ME. Metabolic syndrome and echocardiographic left ventricular mass in blacks: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2005;112:819-27.
34. McNeill AM, Rosamond WD, Girman CJ et al. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am J Cardiol 2004;94:1249-54.
35. Tzou WS, Douglas PS, Srinivasan SR. Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study. J Am Coll Cardiol 2005;46:457-63.
36. Grundy SM, Cleeman JI, Bairey-Merz N et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39.
37. Vasan RS, Larson MG, Leip EP et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in The Framingham Heart Study. Lancet 2001;358:1682-6.
38. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003;289: 2560-72.
39. Pearson TA, Blair SN, Daniels SR et al. American Heart Association guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106:388-91.